Biotechnology

Sanyou Super Trillion Peptide Molecule Discovery Platform Officially Launched Today

SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- On January 13, 2024 local time, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of its "Sanyou Super Trillion Peptide Molecule Discovery Platform". The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral ...

2024-01-20 08:00 2220

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2024 American Society of Clinical Oncology Gastrointestin...

2024-01-19 21:50 1482

Top Employer 2024 certification reflects Boehringer Ingelheim Vietnam's impactful people development

HO CHI MINH CITY, Vietnam, Jan. 19, 2024 /PRNewswire/ -- For the fifth consecutive year, Boehringer Ingelheim Vietnam, a biopharmaceutical company focused on research, has received recognition for its exceptionalworkplace. Globally, Boehringer Ingelheim has been recognized as a "Global Top Employ...

2024-01-19 19:28 1511

Call for Application for 2024 Tsinghua Amgen Scholars Program

BEIJING, Jan. 19, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thr...

2024-01-19 15:32 2441

Harbour BioMed Announces Positive Profit Alert

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-01-19 12:52 4923

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

IRVINE, Calif., Jan. 18, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia (...

2024-01-18 16:00 2142

Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Asia Pacific

* Boehringer Ingelheim is recognized as one of 17 Top Employers worldwide and for the fifth consecutive year inAsia Pacific * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development...

2024-01-18 12:00 1432

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in theUSA * The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in theUSA MELBOURNE, Australia ,Jan. ...

2024-01-18 10:31 1118

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansionshowed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - - Preliminary survival analysis of ADG126 10 mg/kg do...

2024-01-17 20:00 2169

WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, highly flexible engineering platform that greatly enhances the deve...

2024-01-17 08:30 3726

Complete Genomics and Gencove Announce agreement at Plant and Animal Genome Conference (PAG 31) to offer a bundled solution for low-pass whole genome sequencing

SAN JOSE, Calif., Jan. 16, 2024 /PRNewswire/ -- Complete Genomics , a life sciences company that provides novel, end-to-end DNA sequencing solutions, today announced a joint marketing agreement withGencove,  a pioneer of low-pass whole gen...

2024-01-16 22:00 1283

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

This study aims to compare the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease with the goal of informing practice guidelines around which modality is best suited for patients with this...

2024-01-16 21:00 1219

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that onJanuary 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center inChina,...

2024-01-16 17:00 1645

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

STIC CTC trial data published this November 2023 in the Journal of Clinical Oncology (JCO)demonstrate that CTC-guided treatment decision confers superior survival benefits in a subgroup of patients with hormone receptor (HR) positive)/human epidermal growth factor receptor (HER) 2 negative metast...

2024-01-16 15:00 1239

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypic...

2024-01-15 21:50 1365

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care inIndia BOSTON and ROLLE, Switzerland, Jan. 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (N...

2024-01-15 12:00 1326

Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia

SHANGHAI, Jan. 14, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, "An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgene...

2024-01-15 08:08 1299

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus toSan Francisco. The J.P. Morgan Healthcare Conference has been successfully held here for 42 editions, becoming a hall where industry thought converges and spar...

2024-01-12 23:28 5840

Subject Enrollment Completed for International Multicenter Comparative Clinical (Phase 3) Study of Boan Biotech's Denosumab

A meeting was also held in Germany to announce the results of the international pharmacokinetic similarity clinical (Phase 1) study BERLIN, Jan. 12, 2024 /PRNewswire/ -- Boan Biotech recently announced that subject enrollment for the international multicenter comparative clinical (Phase 3) study...

2024-01-12 21:15 2332

Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI ) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJanuary 10, 2024,...

2024-01-12 20:30 5213
1 ... 10111213141516 ... 275

Week's Top Stories